☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
psoriatic arthritis
AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis...
November 10, 2021
AbbVie's Rinvoq (upadacitinib) Receives the Health Canada's Approval for the Treatment of Psoriatic Arthritis
June 8, 2021
AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis
April 8, 2021
Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis
March 17, 2021
AbbVie's Rinvoq (upadacitinib) Receives the EC's Approval for Psoriatic Arthritis and Ankylosing Spondylitis
January 27, 2021
Novartis Reports Results of Cosentyx (secukinumab) in P-IIIb ULTIMATE Study for Psoriatic Arthritis
November 5, 2020
Load more...
Back to Home